NCT02126371

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor"), with an aim to help people with skin conditions called psoriasis. The aim (s) of this Study are to determine: * The effects of the Study Drug when given as different formulations intended for oral administration (tablets and capsules) * The safety of the Study Drug and any side effects that might be associated with it * The effect of food on the Study Drug * The Study will also measure how much of the Study Drug gets into the blood stream and how long it takes the body to remove it and what affect the Study Drug has on the body.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	LEO32731

Timeline

• Start date: 2014-05-01
• Primary completion: 2015-01-01
• Completion: 2015-01-01
• First posted: 2014-04-30
• Last updated: 2016-06-14

Locations

1 site across 1 country: United Kingdom